Catalent to sell its Nottingham oral solid dose facility to CDMO Codis
read at Endpoints ↗DealNeutral
Catalent announced it will divest its United Kingdom manufacturing site, selling the oral solid dose factory located in Nottingham.
The buyer is Codis, a contract development and manufacturing organization, which will take over the facility as part of its CDMO portfolio.
The transaction is part of Catalent's broader effort to reshape its asset base. Other industry updates include manufacturing build announcements from Rottendorf and Evonik, as well as news involving RoslinCT and Novo Nordisk.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Catalent to divest UK site; Rottendorf, Evonik announce manufacturing builds”
read at Endpoints ↗76 words · retrieved Jul 9
comments(0)
5-min edit window · permanent after that